Observational studyEuropean journal of neurology2025
Unlocking Relief: Investigating the Impact of a Fixed Combination of Acetyl-L-Carnitine and Palmitoylethanolamide on Traumatic Acute Low Back Pain.
Observational study in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Acetyl-L-Carnitine in the Treatment of Peripheral Neuropathies: A Narrative Review.Pain and therapy · 2026Review
- Real-World Before-After Study ofNutrients · 2026Article
- Thyroid diseases and risk of peripheral neuropathy in a large population-based cohort: evidence from the UK Biobank.Frontiers in endocrinology · 2026Article
- Efficacy and Safety ofPharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPeripheral neuropathies encompass a diverse group of disorders involving peripheral nerve damage, often leading to pain, sensory disturbances, and motor impairments. The etiology is multifactorial, with trauma as a key contributor. The treatment of peripheral neuropathies includes medications targeting the nociceptive component, whereas the neuropathic component is managed with agents such as gabapentinoids or antidepressants, though their prolonged use is limited by significant side effects. Some neuroprotective compounds, such as acetyl-L-carnitine (ALC), palmitoylethanolamide (PEA), and alpha-lipoic acid (ALA), have emerged as potential alternatives due to their anti-inflammatory and analgesic properties.
methodsThis monocentric, observational, single-arm longitudinal study evaluated the efficacy of a fixed combination containing ALC, PEA, and ALA (as an adjuvant to the previous two) and Boswellia serrata, Vitamin E, and Vitamin B6 in patients with acute low back trauma. Over 8 weeks, 48 participants received the supplement alongside conventional therapy. The primary end point was improvement in neuropathic pain assessed via the Neuropathic Pain Scale (NPS) and Visual Analogue Scale (VAS). Secondary endpoints included quality of life (SF-36) changes, reduced NSAID consumption, and adverse events.
resultsThe study showed significant reductions in NPS and VAS scores and improvements in physical health-related SF-36 domains, with reduced NSAID consumption. Participants with more severe baseline symptoms demonstrated the greatest benefits. No significant changes were observed in emotional parameters. Adverse events were mild and in a very limited number of patients.
conclusionsResults suggest the combination's potential to improve pain and reduce reliance on conventional therapies; however, further controlled randomized trials are needed to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.